P11021
SS
Gene name |
HSPA5 (GRP78) |
Protein name |
Endoplasmic reticulum chaperone BiP |
Names |
EC 3.6.4.10 , 78 kDa glucose-regulated protein , GRP-78 , Binding-immunoglobulin protein , BiP , Heat shock protein 70 family protein 5 , HSP70 family protein 5 , Heat shock protein family A member 5 , Immunoglobulin heavy chain-binding protein |
Species |
Homo sapiens (Human) |
KEGG Pathway |
hsa:3309 |
EC number |
3.6.4.10: Acting on ATP; involved in cellular and subcellular movement |
Protein Class |
|
Descriptions
HSPA8 (or hsc70) is a heat shock cognate protein involved in many cellular processes. During recovery from stress, HSPA8, initially accumulating in the nucleoplasm for folding/refolding of proteins, transiently concentrates in nucleoli for nucleolar morphology and function restoration. The inhibitory region is positioned at one of the three domains of HSPA8 protein, which is the N-terminal ATPase domain, specifically in residues 263-287 of domain IIB. Under normal growth conditions, the constitutive nucleolar targeting function that is provided by residues 225-262 is diminished by the autoinhibitory element located in residues 263-287. When cells recover from stress, the autoinhibitory element is inactivated, and the constitutive nucleolar targeting function restores.
Autoinhibitory domains (AIDs)
Target domain |
250-287 (Nucleolar targeting region) |
Relief mechanism |
Others |
Assay |
|
Accessory elements
No accessory elements
Autoinhibited structure
Activated structure
24 structures for P11021
| Entry ID | Method | Resolution | Chain | Position | Source |
|---|---|---|---|---|---|
| 3IUC | X-ray | 240 A | A/C | 26-410 | PDB |
| 3LDL | X-ray | 230 A | A/B | 26-407 | PDB |
| 3LDN | X-ray | 220 A | A/B | 26-407 | PDB |
| 3LDO | X-ray | 195 A | A/B | 26-407 | PDB |
| 3LDP | X-ray | 220 A | A/B | 26-407 | PDB |
| 5E84 | X-ray | 299 A | A/B/C/D/E/F | 25-633 | PDB |
| 5E85 | X-ray | 257 A | A | 418-637 | PDB |
| 5E86 | X-ray | 268 A | A | 418-637 | PDB |
| 5EVZ | X-ray | 185 A | A/B | 26-407 | PDB |
| 5EX5 | X-ray | 190 A | A/B | 26-407 | PDB |
| 5EXW | X-ray | 190 A | A/B | 26-407 | PDB |
| 5EY4 | X-ray | 186 A | A/B | 26-407 | PDB |
| 5F0X | X-ray | 160 A | A/B | 26-407 | PDB |
| 5F1X | X-ray | 190 A | A/B | 26-407 | PDB |
| 5F2R | X-ray | 215 A | A/B | 26-407 | PDB |
| 6ASY | X-ray | 185 A | A/B | 25-633 | PDB |
| 6CZ1 | X-ray | 168 A | A/B | 26-407 | PDB |
| 6DFM | X-ray | 214 A | A/B | 26-407 | PDB |
| 6DFO | X-ray | 254 A | A/B | 26-407 | PDB |
| 6DO2 | X-ray | 170 A | A/B | 26-407 | PDB |
| 6DWS | X-ray | 190 A | A/B | 26-407 | PDB |
| 6ZMD | X-ray | 264 A | A | 28-549 | PDB |
| 7N1R | X-ray | 203 A | A/B | 25-633 | PDB |
| AF-P11021-F1 | Predicted | AlphaFoldDB |
404 variants for P11021
| Variant ID(s) | Position | Change | Description | Diseaes Association | Provenance |
|---|---|---|---|---|---|
| rs373628096 | 2 | K>M | No |
ESP ExAC TOPMed gnomAD |
|
| rs918826597 | 2 | K>Q | No |
TOPMed gnomAD |
|
| rs1832560045 | 3 | L>F | No | TOPMed | |
|
COSM3654337 rs774479903 |
4 | S>F | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA Cosmic ExAC NCI-TCGA TOPMed gnomAD |
| rs1279993952 | 5 | L>P | No |
TOPMed gnomAD |
|
| rs1235678444 | 5 | L>V | No | TOPMed | |
| rs1832559803 | 6 | V>A | No | Ensembl | |
| TCGA novel | 7 | A>D | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1588432007 | 7 | A>S | No | Ensembl | |
| rs1168692147 | 10 | L>P | No | gnomAD | |
| rs1832559528 | 12 | L>M | No | TOPMed | |
| rs1452694680 | 13 | L>P | No | gnomAD | |
| rs1588431973 | 14 | S>G | No | Ensembl | |
| rs781032276 | 14 | S>R | No |
ExAC TOPMed gnomAD |
|
| rs1588431963 | 15 | A>T | No | Ensembl | |
| rs1179512258 | 15 | A>V | No | gnomAD | |
| rs756929764 | 16 | A>V | No |
ExAC gnomAD |
|
| rs1202257346 | 17 | R>L | No |
TOPMed gnomAD |
|
| rs1202257346 | 17 | R>Q | No |
TOPMed gnomAD |
|
| rs2131455380 | 18 | A>P | No | Ensembl | |
| TCGA novel | 18 | A>V | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1564208377 | 20 | E>K | No | Ensembl | |
| rs980600790 | 21 | E>K | No | TOPMed | |
| rs752211105 | 22 | D>G | No |
ExAC TOPMed gnomAD |
|
| rs758001741 | 22 | D>N | No |
ExAC TOPMed gnomAD |
|
| rs766831759 | 23 | K>E | No |
ExAC TOPMed gnomAD |
|
| rs1832558702 | 23 | K>R | No | TOPMed | |
| rs1223996848 | 24 | K>E | No |
TOPMed gnomAD |
|
| rs1832558604 | 24 | K>N | No | Ensembl | |
| rs1442272847 | 26 | D>E | No |
TOPMed gnomAD |
|
| rs61999288 | 26 | D>N | No |
ExAC TOPMed gnomAD |
|
| rs750811646 | 27 | V>M | No |
ExAC gnomAD |
|
| rs1394566736 | 29 | T>M | No | gnomAD | |
| rs1588431888 | 31 | V>G | No | Ensembl | |
| TCGA novel | 35 | L>M | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 36 | G>R | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1832558070 | 40 | S>P | No | Ensembl | |
| rs1335155867 | 41 | C>* | No |
1000Genomes TOPMed gnomAD |
|
| rs1832556452 | 44 | V>A | No | TOPMed | |
| rs1231899934 | 45 | F>L | No | gnomAD | |
| rs1355193954 | 46 | K>* | No | gnomAD | |
| rs1832556331 | 46 | K>N | No | TOPMed | |
| rs1832556277 | 48 | G>S | No |
TOPMed gnomAD |
|
| rs1832556244 | 49 | R>L | No | TOPMed | |
| rs1237147765 | 50 | V>M | No | Ensembl | |
|
rs377512653 TCGA novel |
65 | Y>C | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No |
NCI-TCGA ESP ExAC TOPMed gnomAD |
| rs377512653 | 65 | Y>F | No |
ESP ExAC TOPMed gnomAD |
|
| rs759479785 | 66 | V>I | No |
ExAC TOPMed |
|
| rs77384477 | 68 | F>Y | No | Ensembl | |
| rs746836983 | 70 | P>L | No |
ExAC gnomAD |
|
| rs200897884 | 70 | P>S | No |
1000Genomes ExAC TOPMed gnomAD |
|
| COSM4929070 | 70 | P>T | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| COSM3847651 | 71 | E>K | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
|
TCGA novel rs777686093 |
73 | E>G | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No |
NCI-TCGA ExAC gnomAD |
| rs1832555129 | 87 | N>S | No | Ensembl | |
| rs754529165 | 89 | E>D | No |
ExAC gnomAD |
|
| rs373292645 | 89 | E>K | No |
ESP ExAC TOPMed gnomAD |
|
| rs1187454921 | 90 | N>K | No | gnomAD | |
| COSM1105158 | 92 | V>I | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| TCGA novel | 97 | R>W | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1211390286 | 99 | I>M | No | gnomAD | |
| rs757741308 | 102 | T>M | No |
ExAC TOPMed gnomAD |
|
| rs1832554441 | 103 | W>* | No | TOPMed | |
| TCGA novel | 103 | W>R | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1832554391 | 104 | N>H | No | Ensembl | |
| rs1832554328 | 106 | P>A | No | TOPMed | |
| rs764437821 | 107 | S>A | No |
ExAC gnomAD |
|
| rs758699653 | 110 | Q>E | No |
ExAC TOPMed gnomAD |
|
| rs201412581 | 112 | I>V | No | 1000Genomes | |
| rs1832553881 | 113 | K>E | No | Ensembl | |
| rs1373246412 | 113 | K>N | No |
TOPMed gnomAD |
|
| rs752980725 | 116 | P>Q | No |
ExAC gnomAD |
|
| rs1832553741 | 116 | P>S | No | gnomAD | |
| TCGA novel | 119 | V>A | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs778199015 | 120 | V>A | No |
ExAC gnomAD |
|
| rs2131454777 | 123 | K>R | No | Ensembl | |
| rs928673869 | 128 | I>V | No | Ensembl | |
|
COSM3847650 rs191087735 |
132 | I>T | Variant assessed as Somatic; MODERATE impact. breast [NCI-TCGA, Cosmic] | No |
NCI-TCGA Cosmic cosmic curated 1000Genomes ExAC NCI-TCGA TOPMed gnomAD |
| rs1364066030 | 133 | G>R | No | gnomAD | |
| rs1183495817 | 135 | G>R | No | gnomAD | |
| rs1417734683 | 136 | Q>H | No | gnomAD | |
| rs765533290 | 137 | T>I | No |
ExAC TOPMed gnomAD |
|
| rs1044787540 | 138 | K>E | No | Ensembl | |
| COSM3847649 | 138 | K>N | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs755130497 | 139 | T>I | No |
ExAC TOPMed gnomAD |
|
| rs755130497 | 139 | T>K | No |
ExAC TOPMed gnomAD |
|
| rs1212235788 | 142 | P>S | No | gnomAD | |
| rs1373860864 | 144 | E>Q | No | TOPMed | |
| rs1278798103 | 148 | M>V | No |
TOPMed gnomAD |
|
| rs747489527 | 151 | T>A | No | Ensembl | |
| rs1199995948 | 151 | T>N | No |
TOPMed gnomAD |
|
| rs1351458297 | 153 | M>I | No | gnomAD | |
| rs760769294 | 155 | E>D | No |
ExAC TOPMed gnomAD |
|
| rs766559685 | 155 | E>K | No | ExAC | |
| COSM3654336 | 158 | E>K | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1287411884 | 162 | G>R | No | gnomAD | |
| rs1588431064 | 166 | T>P | No | Ensembl | |
| rs1475987193 | 167 | H>P | No |
TOPMed gnomAD |
|
| rs1832536702 | 168 | A>G | No |
TOPMed gnomAD |
|
| COSM1105157 | 174 | A>T | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1564207723 | 180 | Q>H | No | TOPMed | |
| rs1832536174 | 185 | K>E | No | gnomAD | |
| rs1832536141 | 186 | D>G | No | gnomAD | |
| rs769398663 | 187 | A>S | No |
ExAC gnomAD |
|
| rs1340057768 | 188 | G>R | No | gnomAD | |
| rs759090127 | 189 | T>I | No |
ExAC gnomAD |
|
| rs759090127 | 189 | T>N | No |
ExAC gnomAD |
|
| COSM1105156 | 189 | T>P | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1832535976 | 190 | I>V | No |
TOPMed gnomAD |
|
| rs1013457166 | 191 | A>S | No | Ensembl | |
| rs1832535901 | 192 | G>D | No | Ensembl | |
| rs1389938825 | 192 | G>S | No | TOPMed | |
| rs1832535843 | 193 | L>V | No | TOPMed | |
| rs1832535805 | 194 | N>S | No | TOPMed | |
| rs1225600593 | 195 | V>I | No | gnomAD | |
| rs2131454302 | 196 | M>I | No | Ensembl | |
| rs1229759275 | 196 | M>T | No | gnomAD | |
| rs776093278 | 197 | R>M | No | ExAC | |
| rs1175929824 | 198 | I>M | No |
TOPMed gnomAD |
|
| rs748594236 | 198 | I>T | No | ExAC | |
| rs1832535586 | 199 | I>V | No | gnomAD | |
| rs749620773 | 200 | N>K | No |
ExAC TOPMed gnomAD |
|
| rs779406868 | 200 | N>S | No |
ExAC gnomAD |
|
| rs1465755612 | 202 | P>L | No | TOPMed | |
| rs1588430967 | 205 | A>G | No | Ensembl | |
| TCGA novel | 210 | G>D | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| COSM3904076 | 211 | L>M | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1588430963 | 212 | D>G | No | Ensembl | |
| rs1588430955 | 215 | E>A | No | Ensembl | |
| rs777435502 | 215 | E>D | No |
ExAC gnomAD |
|
| rs1588430955 | 215 | E>G | No | Ensembl | |
| rs1832534088 | 216 | G>W | No | TOPMed | |
| rs1443431270 | 217 | E>D | No | gnomAD | |
| rs1588430953 | 217 | E>G | No | Ensembl | |
| COSM5106644 | 217 | E>R | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| COSM5156043 | 218 | K>missing | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1306743375 | 219 | N>S | No | gnomAD | |
| rs998102632 | 220 | I>L | No | gnomAD | |
| rs998102632 | 220 | I>V | No | gnomAD | |
| COSM4929196 | 223 | F>V | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1429609324 | 225 | L>P | No | gnomAD | |
| rs746095580 | 237 | I>T | No |
ExAC gnomAD |
|
| rs200482739 | 239 | N>S | No | gnomAD | |
| COSM1105155 | 240 | G>D | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| TCGA novel | 247 | T>Y | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No | NCI-TCGA |
| rs189604329 | 248 | N>S | No | 1000Genomes | |
| rs1832533296 | 251 | T>S | No | gnomAD | |
| rs11542738 | 257 | D>Y | No | Ensembl | |
| rs185877709 | 261 | R>C | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs752543561 | 261 | R>H | No |
ExAC gnomAD |
|
| rs1832532761 | 265 | H>R | No | TOPMed | |
| rs765009153 | 267 | I>L | No |
ExAC TOPMed gnomAD |
|
| rs1832532669 | 268 | K>Q | No | Ensembl | |
| rs1832532522 | 272 | K>E | No | TOPMed | |
| rs1832532500 | 273 | K>R | No | gnomAD | |
| rs753498680 | 274 | T>M | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
ExAC NCI-TCGA TOPMed gnomAD |
| rs1217112485 | 275 | G>C | No |
TOPMed gnomAD |
|
| rs1832532361 | 275 | G>V | No | Ensembl | |
| TCGA novel | 276 | K>R | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1358602635 | 277 | D>A | No | gnomAD | |
|
COSM169742 rs927584824 |
277 | D>Y | Variant assessed as Somatic; MODERATE impact. large_intestine [NCI-TCGA, Cosmic] | No |
cosmic curated NCI-TCGA TOPMed gnomAD |
| rs1832532245 | 279 | R>S | No | TOPMed | |
| rs557143437 | 280 | K>N | No | Ensembl | |
| rs1564207523 | 280 | K>T | No | Ensembl | |
| rs1832532149 | 282 | N>S | No | gnomAD | |
| rs1410032554 | 283 | R>K | No |
TOPMed gnomAD |
|
| rs1588430869 | 284 | A>D | No | Ensembl | |
| rs1415653914 | 284 | A>T | No |
TOPMed gnomAD |
|
| rs201219378 | 285 | V>A | No | 1000Genomes | |
| COSM487041 | 288 | L>V | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1258181789 | 290 | R>C | No | gnomAD | |
| rs1183483292 | 290 | R>H | No |
TOPMed gnomAD |
|
| rs772745555 | 291 | E>K | No |
ExAC gnomAD |
|
| rs772745555 | 291 | E>Q | No |
ExAC gnomAD |
|
| COSM5231001 | 295 | A>P | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1832531712 | 295 | A>S | No | gnomAD | |
| rs764555947 | 297 | R>W | No |
ExAC gnomAD |
|
| rs1179967296 | 302 | Q>L | No | gnomAD | |
| rs763551125 | 305 | A>V | No |
ExAC gnomAD |
|
| rs776075958 | 309 | I>T | No |
ExAC TOPMed gnomAD |
|
| COSM752720 | 312 | F>S | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs545601947 | 313 | Y>C | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs545601947 | 313 | Y>F | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs1832531252 | 313 | Y>H | No | Ensembl | |
| rs1394745428 | 316 | E>G | No | gnomAD | |
| rs1832531031 | 318 | F>S | No | Ensembl | |
| rs746186875 | 318 | F>V | No |
ExAC TOPMed gnomAD |
|
| rs776753213 | 319 | S>T | No |
ExAC gnomAD |
|
| rs1432966367 | 321 | T>I | No | gnomAD | |
| rs1398549715 | 323 | T>S | No | Ensembl | |
| rs762582529 | 324 | R>Q | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA TOPMed |
| rs916098425 | 324 | R>W | No | Ensembl | |
| rs866597853 | 325 | A>T | No | Ensembl | |
| rs747110106 | 326 | K>R | No |
ExAC TOPMed gnomAD |
|
| rs947809704 | 329 | E>D | No | TOPMed | |
|
COSM752721 rs772811684 |
332 | M>I | lung [Cosmic] | No |
cosmic curated ExAC gnomAD |
| rs150434402 | 332 | M>V | No |
ESP ExAC TOPMed gnomAD |
|
| rs1454496285 | 333 | D>A | No | gnomAD | |
| rs61755726 | 333 | D>E | No | Ensembl | |
| rs1252434461 | 336 | R>L | No |
TOPMed gnomAD |
|
| rs1252434461 | 336 | R>Q | No |
TOPMed gnomAD |
|
| rs1488339886 | 336 | R>W | No |
TOPMed gnomAD |
|
| rs768548100 | 338 | T>A | No |
ExAC gnomAD |
|
| rs1832527975 | 339 | M>R | No | TOPMed | |
| rs1370988503 | 339 | M>V | No | Ensembl | |
| rs779884716 | 340 | K>R | No |
ExAC gnomAD |
|
| rs779884716 | 340 | K>T | No |
ExAC gnomAD |
|
| rs750103794 | 342 | V>I | No |
ExAC gnomAD |
|
| COSM74952 | 343 | Q>H | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1386517735 | 347 | E>K | No | gnomAD | |
| rs1832527587 | 350 | D>G | No | TOPMed | |
| rs1832527530 | 351 | L>F | No | TOPMed | |
| TCGA novel | 352 | K>N | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs935054387 | 353 | K>* | No | Ensembl | |
| rs1368629912 | 354 | S>F | No | gnomAD | |
| TCGA novel | 356 | I>S | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 356 | I>T | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1832527414 | 356 | I>V | No | gnomAD | |
| rs760079687 | 357 | D>N | No |
ExAC TOPMed gnomAD |
|
| rs1832527306 | 358 | E>V | No | TOPMed | |
| TCGA novel | 361 | L>H | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1343403693 | 361 | L>I | No |
TOPMed gnomAD |
|
| rs1832527216 | 361 | L>P | No | TOPMed | |
| rs1188284635 | 369 | P>S | No | TOPMed | |
| rs766767689 | 370 | K>E | No |
ExAC gnomAD |
|
| rs746945148 | 371 | I>M | No | TOPMed | |
| rs1351604160 | 372 | Q>E | No |
TOPMed gnomAD |
|
| rs866590944 | 373 | Q>* | No | Ensembl | |
| rs866590944 | 373 | Q>K | No | Ensembl | |
| rs772238271 | 377 | E>G | No |
ExAC gnomAD |
|
| rs1482398176 | 377 | E>Q | No | gnomAD | |
| rs772238271 | 377 | E>V | No |
ExAC gnomAD |
|
| rs1832526471 | 380 | N>D | No | TOPMed | |
| COSM752722 | 380 | N>K | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs761919160 | 380 | N>S | No |
ExAC TOPMed gnomAD |
|
| TCGA novel | 381 | G>D | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs200135468 | 382 | K>R | No | 1000Genomes | |
| rs868145616 | 384 | P>L | No | Ensembl | |
| rs1832526279 | 384 | P>T | No | TOPMed | |
| COSM6182296 | 385 | S>C | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs774390329 | 386 | R>H | No |
ExAC gnomAD |
|
|
COSM244969 rs1330307450 |
387 | G>D | Variant assessed as Somatic; MODERATE impact. prostate [NCI-TCGA, Cosmic] | No |
NCI-TCGA Cosmic cosmic curated NCI-TCGA gnomAD |
| rs768638015 | 388 | I>T | No |
ExAC gnomAD |
|
| TCGA novel | 391 | D>Y | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs200526775 | 393 | A>T | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
1000Genomes NCI-TCGA |
| rs1588430623 | 404 | V>G | No | Ensembl | |
| rs1832525752 | 406 | S>C | No | TOPMed | |
| rs1170461542 | 408 | D>G | No | Ensembl | |
| rs751174810 | 408 | D>N | No |
ExAC gnomAD |
|
| COSM1105154 | 410 | D>Y | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs568812325 | 413 | D>E | No |
1000Genomes ExAC gnomAD |
|
| COSM6114666 | 417 | L>F | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs757549614 | 419 | V>I | No |
ExAC gnomAD |
|
| rs1356972308 | 422 | L>V | No |
TOPMed gnomAD |
|
| rs759914509 | 424 | L>F | No | Ensembl | |
| rs1282333876 | 426 | I>V | No | gnomAD | |
| rs1265027435 | 432 | V>I | No | Ensembl | |
| rs1267765504 | 433 | M>V | No | gnomAD | |
| rs751803191 | 435 | K>R | No |
ExAC TOPMed gnomAD |
|
| rs1832521858 | 438 | P>A | No | Ensembl | |
| TCGA novel | 438 | P>S | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs763135186 | 443 | V>M | No |
ExAC gnomAD |
|
| rs1324691272 | 445 | T>S | No | gnomAD | |
| TCGA novel | 446 | K>N | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1832521685 | 446 | K>R | No | TOPMed | |
| rs775411427 | 449 | Q>H | No |
ExAC gnomAD |
|
| rs1832521424 | 454 | A>V | No | TOPMed | |
| rs922711765 | 455 | S>F | No | Ensembl | |
| COSM3654334 | 457 | N>K | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs535209940 | 457 | N>Y | No |
1000Genomes ExAC gnomAD |
|
| rs62580623 | 458 | Q>K | No | Ensembl | |
| rs1253850727 | 459 | P>S | No | gnomAD | |
| rs772946608 | 463 | I>N | No |
ExAC gnomAD |
|
| rs200465691 | 463 | I>V | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
1000Genomes ExAC NCI-TCGA gnomAD |
| rs2131453589 | 464 | K>R | No | Ensembl | |
| rs1832520937 | 466 | Y>C | No | gnomAD | |
| rs761365893 | 471 | P>T | No |
ExAC gnomAD |
|
| rs1472776693 | 474 | K>R | No | gnomAD | |
| TCGA novel | 476 | N>T | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs936657160 | 477 | H>N | No |
TOPMed gnomAD |
|
| rs1253923916 | 483 | D>G | No | gnomAD | |
| rs773987528 | 485 | T>A | No |
ExAC gnomAD |
|
| rs1308682564 | 487 | I>V | No |
TOPMed gnomAD |
|
| TCGA novel | 488 | P>L | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1832508077 | 488 | P>R | No | gnomAD | |
| rs1832508108 | 488 | P>S | No | gnomAD | |
| rs2131452900 | 489 | P>A | No | Ensembl | |
| rs1007136118 | 491 | P>L | No |
TOPMed gnomAD |
|
| rs925239059 | 494 | V>A | No | TOPMed | |
|
TCGA novel rs1211616268 |
496 | Q>H | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA gnomAD |
| TCGA novel | 504 | D>Y | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
|
rs139483439 COSM107841 |
509 | L>F | skin [Cosmic] | No |
cosmic curated Ensembl |
| rs889983653 | 510 | R>G | No | Ensembl | |
| rs1032511460 | 510 | R>Q | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
NCI-TCGA TOPMed gnomAD |
| TCGA novel | 513 | A>P | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| COSM3847648 | 514 | E>Q | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| COSM1314449 | 515 | D>H | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs1588429917 | 515 | D>N | No | Ensembl | |
| rs61740953 | 518 | T>P | No | Ensembl | |
| COSM5161920 | 522 | N>I | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs533357661 | 523 | K>R | No |
1000Genomes TOPMed gnomAD |
|
| rs1445882658 | 526 | I>V | No | gnomAD | |
| rs747433993 | 528 | N>D | No |
ExAC TOPMed gnomAD |
|
| rs1321415640 | 528 | N>S | No | gnomAD | |
| rs758725284 | 529 | D>A | No |
ExAC gnomAD |
|
| rs777998455 | 529 | D>N | No |
ExAC gnomAD |
|
| rs779151361 | 531 | N>T | No |
ExAC gnomAD |
|
| rs755135095 | 532 | R>C | No |
ExAC TOPMed gnomAD |
|
| rs368840257 | 532 | R>H | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
ESP NCI-TCGA TOPMed gnomAD |
| rs368840257 | 532 | R>L | No |
ESP TOPMed gnomAD |
|
| rs1481972967 | 533 | L>V | No |
TOPMed gnomAD |
|
| rs753935146 | 535 | P>L | No |
ExAC TOPMed gnomAD |
|
| COSM3432860 | 537 | E>* | Variant assessed as Somatic; HIGH impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs949430875 | 539 | E>D | No | Ensembl | |
| rs1832505747 | 539 | E>K | No | gnomAD | |
| rs191957514 | 540 | R>S | No |
1000Genomes gnomAD |
|
| rs35356639 | 543 | N>D | No |
1000Genomes TOPMed gnomAD |
|
|
rs35356639 VAR_025815 |
543 | N>H | No |
UniProt 1000Genomes TOPMed dbSNP gnomAD |
|
| rs1832505395 | 549 | A>T | No | TOPMed | |
| rs750297913 | 551 | E>* | No |
ExAC gnomAD |
|
| TCGA novel | 553 | K>N | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1588429813 | 555 | L>I | No | Ensembl | |
|
RCV000915337 rs56136100 |
557 | E>G | No |
ClinVar 1000Genomes ESP ExAC TOPMed dbSNP gnomAD |
|
| rs762500054 | 558 | R>C | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
ExAC NCI-TCGA TOPMed gnomAD |
| rs771497933 | 558 | R>H | No |
ExAC TOPMed gnomAD |
|
| rs771497933 | 558 | R>L | No |
ExAC TOPMed gnomAD |
|
| rs1832504731 | 559 | I>L | No | TOPMed | |
| rs1189961861 | 559 | I>T | No |
TOPMed gnomAD |
|
| rs1832504731 | 559 | I>V | No | TOPMed | |
| rs1421568498 | 561 | T>A | No | gnomAD | |
| rs144050975 | 561 | T>I | No |
ESP ExAC TOPMed gnomAD |
|
| rs144050975 | 561 | T>N | No |
ESP ExAC TOPMed gnomAD |
|
| rs1832504278 | 562 | R>K | No | TOPMed | |
| rs541632037 | 564 | E>D | No |
1000Genomes ExAC gnomAD |
|
| rs1188810256 | 564 | E>K | No | gnomAD | |
| rs1832503982 | 567 | S>T | No | Ensembl | |
| rs1334409215 | 568 | Y>D | No | TOPMed | |
| COSM5145736 | 571 | S>Y | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
|
COSM1105152 rs1588429756 |
573 | K>N | Variant assessed as Somatic; MODERATE impact. endometrium [NCI-TCGA, Cosmic] | No |
NCI-TCGA Cosmic cosmic curated Ensembl |
| rs1588429751 | 574 | N>K | No |
TOPMed gnomAD |
|
| rs1832503414 | 575 | Q>R | No | TOPMed | |
| rs1294335824 | 576 | I>F | No | TOPMed | |
| rs755226649 | 582 | L>P | No |
ExAC gnomAD |
|
| rs755226649 | 582 | L>Q | No |
ExAC gnomAD |
|
| rs1832503112 | 584 | G>V | No | TOPMed | |
| rs1832503072 | 586 | L>P | No | TOPMed | |
| rs1321198633 | 587 | S>T | No | gnomAD | |
| rs572560070 | 589 | E>K | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs1363355640 | 591 | K>Q | No |
TOPMed gnomAD |
|
| rs909088557 | 592 | E>K | No | TOPMed | |
| rs909088557 | 592 | E>Q | No | TOPMed | |
| rs552650805 | 596 | K>E | No |
1000Genomes ExAC gnomAD |
|
| TCGA novel | 598 | V>I | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs79731156 | 600 | E>D | No | TOPMed | |
| rs756195128 | 600 | E>G | No |
ExAC TOPMed gnomAD |
|
| rs77527276 | 601 | K>E | No | Ensembl | |
|
rs143920039 RCV000879264 |
601 | K>M | No |
ClinVar 1000Genomes ExAC TOPMed dbSNP gnomAD |
|
| rs143920039 | 601 | K>T | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs767440147 | 602 | I>T | No |
ExAC TOPMed gnomAD |
|
| rs898175617 | 604 | W>* | No | Ensembl | |
| rs375391643 | 605 | L>V | No |
ESP ExAC TOPMed gnomAD |
|
| TCGA novel | 609 | Q>E | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1005567551 | 610 | D>E | No | Ensembl | |
| rs1191963130 | 613 | I>V | No |
TOPMed gnomAD |
|
| COSM1330732 | 614 | E>D | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs570413832 | 614 | E>K | No |
1000Genomes ExAC TOPMed gnomAD |
|
| rs368193721 | 615 | D>V | No |
ESP ExAC TOPMed gnomAD |
|
|
COSM1460009 rs775060069 |
616 | F>L | Variant assessed as Somatic; MODERATE impact. large_intestine [NCI-TCGA, Cosmic] | No |
NCI-TCGA Cosmic cosmic curated ExAC gnomAD |
| rs1275953631 | 618 | A>D | No | gnomAD | |
| rs374062060 | 618 | A>S | No |
ESP ExAC TOPMed gnomAD |
|
| rs374062060 | 618 | A>T | No |
ESP ExAC TOPMed gnomAD |
|
| rs139238747 | 619 | K>E | No |
ESP TOPMed gnomAD |
|
| rs1588429597 | 619 | K>N | No | Ensembl | |
|
COSM487040 rs773627521 |
621 | K>E | kidney Variant assessed as Somatic; MODERATE impact. [Cosmic, NCI-TCGA] | No |
NCI-TCGA Cosmic cosmic curated ExAC NCI-TCGA TOPMed gnomAD |
| TCGA novel | 621 | K>N | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1167147446 | 622 | E>K | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No |
Ensembl NCI-TCGA |
| rs1564206571 | 625 | E>D | No | Ensembl | |
| rs1303224537 | 626 | I>T | No | gnomAD | |
| rs1588429578 | 626 | I>V | No | Ensembl | |
| rs1384841821 | 627 | V>F | No | gnomAD | |
| COSM3926168 | 627 | V>I | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA Cosmic |
| rs748506361 | 629 | P>S | No |
ExAC gnomAD |
|
| TCGA novel | 630 | I>F | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| TCGA novel | 631 | I>L | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1588429558 | 631 | I>V | No | Ensembl | |
| rs1411145997 | 632 | S>N | No | gnomAD | |
| rs769064758 | 634 | L>R | No |
ExAC TOPMed gnomAD |
|
| rs1564206556 | 635 | Y>H | No | TOPMed | |
| rs1221171418 | 636 | G>A | No |
TOPMed gnomAD |
|
| TCGA novel | 636 | G>E | Variant assessed as Somatic; MODERATE impact. [NCI-TCGA] | No | NCI-TCGA |
| rs1378995475 | 637 | S>N | No | gnomAD | |
| rs1588429524 | 638 | A>G | No | Ensembl | |
| rs756169862 | 638 | A>S | No |
ExAC TOPMed gnomAD |
|
| rs756169862 | 638 | A>T | No |
ExAC TOPMed gnomAD |
|
| rs538500528 | 640 | P>A | No |
1000Genomes ExAC gnomAD |
|
| rs538500528 | 640 | P>T | No |
1000Genomes ExAC gnomAD |
|
| rs781041888 | 641 | P>A | No |
ExAC gnomAD |
|
| rs1832499981 | 641 | P>L | No | TOPMed | |
| rs1249822667 | 642 | P>Q | No | gnomAD | |
| rs757206987 | 642 | P>T | No |
ExAC TOPMed gnomAD |
|
| rs748626391 | 643 | T>P | No | Ensembl | |
| rs752372052 | 646 | E>D | No |
ExAC TOPMed gnomAD |
|
| rs1588429474 | 649 | A>S | No | Ensembl | |
| rs764834058 | 652 | D>E | No |
ExAC TOPMed gnomAD |
1 associated diseases with P11021
Without disease ID
4 regional properties for P11021
| Type | Name | Position | InterPro Accession |
|---|---|---|---|
| conserved_site | Heat shock protein 70, conserved site | 33 - 40 | IPR018181-1 |
| conserved_site | Heat shock protein 70, conserved site | 222 - 235 | IPR018181-2 |
| conserved_site | Heat shock protein 70, conserved site | 359 - 373 | IPR018181-3 |
| domain | Endoplasmic reticulum chaperone BIP, nucleotide-binding domain | 28 - 403 | IPR042050 |
Functions
| Description | ||
|---|---|---|
| EC Number | 3.6.4.10 | Acting on ATP; involved in cellular and subcellular movement |
| Subcellular Localization |
|
|
| PANTHER Family | ||
| PANTHER Subfamily | ||
| PANTHER Protein Class | ||
| PANTHER Pathway Category | No pathway information available | |
18 GO annotations of cellular component
| Name | Definition |
|---|---|
| cell surface | The external part of the cell wall and/or plasma membrane. |
| cytoplasm | The contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures. |
| cytosol | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. |
| endoplasmic reticulum | The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached). |
| endoplasmic reticulum chaperone complex | A protein complex that is located in the endoplasmic reticulum and is composed of chaperone proteins, including BiP, GRP94; CaBP1, protein disulfide isomerase (PDI), ERdj3, cyclophilin B, ERp72, GRP170, UDP-glucosyltransferase, and SDF2-L1. |
| endoplasmic reticulum lumen | The volume enclosed by the membranes of the endoplasmic reticulum. |
| endoplasmic reticulum membrane | The lipid bilayer surrounding the endoplasmic reticulum. |
| endoplasmic reticulum-Golgi intermediate compartment | A complex system of membrane-bounded compartments located between endoplasmic reticulum (ER) and the Golgi complex, with a distinctive membrane protein composition; involved in ER-to-Golgi and Golgi-to-ER transport. |
| extracellular exosome | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. |
| focal adhesion | A cell-substrate junction that anchors the cell to the extracellular matrix and that forms a point of termination of actin filaments. In insects focal adhesion has also been referred to as hemi-adherens junction (HAJ). |
| intracellular membrane-bounded organelle | Organized structure of distinctive morphology and function, bounded by a single or double lipid bilayer membrane and occurring within the cell. Includes the nucleus, mitochondria, plastids, vacuoles, and vesicles. Excludes the plasma membrane. |
| melanosome | A tissue-specific, membrane-bounded cytoplasmic organelle within which melanin pigments are synthesized and stored. Melanosomes are synthesized in melanocyte cells. |
| membrane | A lipid bilayer along with all the proteins and protein complexes embedded in it and attached to it. |
| midbody | A thin cytoplasmic bridge formed between daughter cells at the end of cytokinesis. The midbody forms where the contractile ring constricts, and may persist for some time before finally breaking to complete cytokinesis. |
| mitochondrion | A semiautonomous, self replicating organelle that occurs in varying numbers, shapes, and sizes in the cytoplasm of virtually all eukaryotic cells. It is notably the site of tissue respiration. |
| nucleus | A membrane-bounded organelle of eukaryotic cells in which chromosomes are housed and replicated. In most cells, the nucleus contains all of the cell's chromosomes except the organellar chromosomes, and is the site of RNA synthesis and processing. In some species, or in specialized cell types, RNA metabolism or DNA replication may be absent. |
| plasma membrane | The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins. |
| protein-containing complex | A stable assembly of two or more macromolecules, i.e. proteins, nucleic acids, carbohydrates or lipids, in which at least one component is a protein and the constituent parts function together. |
14 GO annotations of molecular function
| Name | Definition |
|---|---|
| ATP binding | Binding to ATP, adenosine 5'-triphosphate, a universally important coenzyme and enzyme regulator. |
| ATP hydrolysis activity | Catalysis of the reaction |
| ATP-dependent protein folding chaperone | Binding to a protein or a protein-containing complex to assist the protein folding process, driven by ATP hydrolysis. |
| cadherin binding | Binding to cadherin, a type I membrane protein involved in cell adhesion. |
| calcium ion binding | Binding to a calcium ion (Ca2+). |
| enzyme binding | Binding to an enzyme, a protein with catalytic activity. |
| heat shock protein binding | Binding to a heat shock protein, a protein synthesized or activated in response to heat shock. |
| misfolded protein binding | Binding to a misfolded protein. |
| protein domain specific binding | Binding to a specific domain of a protein. |
| protein folding chaperone | Binding to a protein or a protein-containing complex to assist the protein folding process. |
| protein-folding chaperone binding | Binding to a chaperone protein, a class of proteins that bind to nascent or unfolded polypeptides and ensure correct folding or transport. |
| ribosome binding | Binding to a ribosome. |
| ubiquitin protein ligase binding | Binding to a ubiquitin protein ligase enzyme, any of the E3 proteins. |
| unfolded protein binding | Binding to an unfolded protein. |
25 GO annotations of biological process
| Name | Definition |
|---|---|
| cellular response to glucose starvation | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of deprivation of glucose. |
| cellular response to interleukin-4 | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an interleukin-4 stimulus. |
| cerebellar Purkinje cell layer development | The process whose specific outcome is the progression of the cerebellar Purkinje cell layer over time, from its formation to the mature structure. The Purkinje cell layer lies just underneath the molecular layer of the cerebellar cortex. It contains the neuronal cell bodies of the Purkinje cells that are arranged side by side in a single layer. Candelabrum interneurons are vertically oriented between the Purkinje cells. Purkinje neurons are inhibitory and provide the output of the cerebellar cortex through axons that project into the white matter. Extensive dendritic trees from the Purkinje cells extend upward in a single plane into the molecular layer where they synapse with parallel fibers of granule cells. |
| cerebellum structural organization | The process that contributes to the act of creating the structural organization of the cerebellum. This process pertains to the physical shaping of a rudimentary structure. The cerebellum is the portion of the brain in the back of the head between the cerebrum and the pons. The cerebellum controls balance for walking and standing, modulates the force and range of movement and is involved in the learning of motor skills. |
| chaperone cofactor-dependent protein refolding | The process of assisting in the correct posttranslational noncovalent assembly of proteins, which is dependent on additional protein cofactors. This process occurs over one or several cycles of nucleotide hydrolysis-dependent binding and release. |
| endoplasmic reticulum unfolded protein response | The series of molecular signals generated as a consequence of the presence of unfolded proteins in the endoplasmic reticulum (ER) or other ER-related stress; results in changes in the regulation of transcription and translation. |
| ER overload response | The series of molecular signals initiated by the accumulation of normal or misfolded proteins in the endoplasmic reticulum and leading to activation of transcription by NF-kappaB. |
| ERAD pathway | The protein catabolic pathway which targets endoplasmic reticulum (ER)-resident proteins for degradation by the cytoplasmic proteasome. It begins with recognition of the ER-resident protein, includes retrotranslocation (dislocation) of the protein from the ER to the cytosol, protein modifications necessary for correct substrate transfer (e.g. ubiquitination), transport of the protein to the proteasome, and ends with degradation of the protein by the cytoplasmic proteasome. |
| maintenance of protein localization in endoplasmic reticulum | Any process in which a protein is maintained in the endoplasmic reticulum and prevented from moving elsewhere. These include sequestration within the endoplasmic reticulum, protein stabilization to prevent transport elsewhere and the active retrieval of proteins that escape the endoplasmic reticulum. |
| negative regulation of apoptotic process | Any process that stops, prevents, or reduces the frequency, rate or extent of cell death by apoptotic process. |
| negative regulation of IRE1-mediated unfolded protein response | Any process that stops, prevents or reduces the frequency, rate or extent of the IRE1-mediated unfolded protein response. |
| negative regulation of protein-containing complex assembly | Any process that stops, prevents, or reduces the frequency, rate or extent of protein complex assembly. |
| negative regulation of transforming growth factor beta receptor signaling pathway | Any process that stops, prevents, or reduces the frequency, rate or extent of any TGF-beta receptor signaling pathway. |
| positive regulation of cell migration | Any process that activates or increases the frequency, rate or extent of cell migration. |
| positive regulation of protein ubiquitination | Any process that activates or increases the frequency, rate or extent of the addition of ubiquitin groups to a protein. |
| positive regulation of transcription by RNA polymerase II | Any process that activates or increases the frequency, rate or extent of transcription from an RNA polymerase II promoter. |
| post-translational protein targeting to membrane, translocation | The process in which a protein translocates through the ER membrane posttranslationally. |
| protein folding in endoplasmic reticulum | A protein folding process that takes place in the endoplasmic reticulum (ER). Secreted, plasma membrane and organelle proteins are folded in the ER, assisted by chaperones and foldases (protein disulphide isomerases), and additional factors required for optimal folding (ATP, Ca2+ and an oxidizing environment to allow disulfide bond formation). |
| protein refolding | The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones. |
| regulation of ATF6-mediated unfolded protein response | Any process that modulates the frequency, rate or extent of the ATF6-mediated unfolded protein response. |
| regulation of IRE1-mediated unfolded protein response | Any process that modulates the frequency, rate or extent of the IRE1-mediated unfolded protein response. |
| regulation of PERK-mediated unfolded protein response | Any process that modulates the frequency, rate or extent of the PERK-mediated unfolded protein response. |
| regulation of protein folding in endoplasmic reticulum | Any process that modulates the rate, frequency or extent of the protein folding process that takes place in the endoplasmic reticulum (ER). Secreted, plasma membrane and organelle proteins are folded in the ER, assisted by chaperones and foldases (protein disulphide isomerases), and additional factors required for optimal folding (ATP, Ca2+ and an oxidizing environment to allow disulfide bond formation). |
| response to endoplasmic reticulum stress | Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stress acting at the endoplasmic reticulum. ER stress usually results from the accumulation of unfolded or misfolded proteins in the ER lumen. |
| substantia nigra development | The progression of the substantia nigra over time from its initial formation until its mature state. The substantia nigra is the layer of gray substance that separates the posterior parts of the cerebral peduncles (tegmentum mesencephali) from the anterior parts; it normally includes a posterior compact part with many pigmented cells (pars compacta) and an anterior reticular part whose cells contain little pigment (pars reticularis). |
11 homologous proteins in AiPD
| UniProt AC | Gene Name | Protein Name | Species | Evidence Code |
|---|---|---|---|---|
| P77319 | hscC | Chaperone protein HscC | Escherichia coli (strain K12) | PR |
| P0A6Y8 | dnaK | Chaperone protein DnaK | Escherichia coli (strain K12) | SS |
| P0DMV9 | HSPA1B | Heat shock 70 kDa protein 1B | Homo sapiens (Human) | SS |
| P38646 | HSPA9 | Stress-70 protein, mitochondrial | Homo sapiens (Human) | SS |
| P17066 | HSPA6 | Heat shock 70 kDa protein 6 | Homo sapiens (Human) | SS |
| P0DMV8 | HSPA1A | Heat shock 70 kDa protein 1A | Homo sapiens (Human) | SS |
| P34931 | HSPA1L | Heat shock 70 kDa protein 1-like | Homo sapiens (Human) | SS |
| Q0VDF9 | HSPA14 | Heat shock 70 kDa protein 14 | Homo sapiens (Human) | SS |
| P54652 | HSPA2 | Heat shock-related 70 kDa protein 2 | Homo sapiens (Human) | SS |
| P11142 | HSPA8 | Heat shock cognate 71 kDa protein | Homo sapiens (Human) | EV |
| P48741 | HSPA7 | Putative heat shock 70 kDa protein 7 | Homo sapiens (Human) | SS |
| 10 | 20 | 30 | 40 | 50 | 60 |
| MKLSLVAAML | LLLSAARAEE | EDKKEDVGTV | VGIDLGTTYS | CVGVFKNGRV | EIIANDQGNR |
| 70 | 80 | 90 | 100 | 110 | 120 |
| ITPSYVAFTP | EGERLIGDAA | KNQLTSNPEN | TVFDAKRLIG | RTWNDPSVQQ | DIKFLPFKVV |
| 130 | 140 | 150 | 160 | 170 | 180 |
| EKKTKPYIQV | DIGGGQTKTF | APEEISAMVL | TKMKETAEAY | LGKKVTHAVV | TVPAYFNDAQ |
| 190 | 200 | 210 | 220 | 230 | 240 |
| RQATKDAGTI | AGLNVMRIIN | EPTAAAIAYG | LDKREGEKNI | LVFDLGGGTF | DVSLLTIDNG |
| 250 | 260 | 270 | 280 | 290 | 300 |
| VFEVVATNGD | THLGGEDFDQ | RVMEHFIKLY | KKKTGKDVRK | DNRAVQKLRR | EVEKAKRALS |
| 310 | 320 | 330 | 340 | 350 | 360 |
| SQHQARIEIE | SFYEGEDFSE | TLTRAKFEEL | NMDLFRSTMK | PVQKVLEDSD | LKKSDIDEIV |
| 370 | 380 | 390 | 400 | 410 | 420 |
| LVGGSTRIPK | IQQLVKEFFN | GKEPSRGINP | DEAVAYGAAV | QAGVLSGDQD | TGDLVLLDVC |
| 430 | 440 | 450 | 460 | 470 | 480 |
| PLTLGIETVG | GVMTKLIPRN | TVVPTKKSQI | FSTASDNQPT | VTIKVYEGER | PLTKDNHLLG |
| 490 | 500 | 510 | 520 | 530 | 540 |
| TFDLTGIPPA | PRGVPQIEVT | FEIDVNGILR | VTAEDKGTGN | KNKITITNDQ | NRLTPEEIER |
| 550 | 560 | 570 | 580 | 590 | 600 |
| MVNDAEKFAE | EDKKLKERID | TRNELESYAY | SLKNQIGDKE | KLGGKLSSED | KETMEKAVEE |
| 610 | 620 | 630 | 640 | 650 | |
| KIEWLESHQD | ADIEDFKAKK | KELEEIVQPI | ISKLYGSAGP | PPTGEEDTAE | KDEL |